Document is current
Any future updates will be listed below
-
Authors
Aboseif, Albert
Jackson-Tarlton, Caitlin S.
Schwarz, Christopher G.
Decker, Paul A.
Kosel, Matthew L.
Son, Jiye
Keegan, B. Mark
Kantarci, Kejal
Eckel-Passow, Jeanette E.
Kantarci, Orhun H.
Zeydan, Burcu
Tobin, W. Oliver https://orcid.org/0000-0002-8141-2394
- License Information
-
More Information
Article History
Received: 11 June 2025
Revised: 22 September 2025
Accepted: 26 September 2025
First Online: 21 October 2025
Declarations
:
: Albert Aboseif is sponsored by the Eugene and Marcia Applebaum Fellowship Award through the Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic. Caitlin S. Jackson-Tarlton reports consulting/advisory for EMD Serono, Novartis, Roche, Biogen, Amgen Horizon, and clinical trial support from Roche. Christopher G. Schwarz receives research funding from NIH. Paul A. Decker reports no disclosures. Matthew L. Kosel reports no disclosures. B. Mark Keegan reports consulting for EMD Serono, Tr1X, Inc, Moderna, royalties from Oxford University Press Mayo Clinic Cases in Neuroimmunology. Kejal Kantarci serves on the Data Safety Monitoring Board for Takeda Pharmaceuticals. She is funded by the National Institutes of Health. Jeanette E. Eckel-Passow reports no disclosures Orhun H. Kantarci reports no disclosures. Burcu Zeydan receives funding from the National Institutes of Health [K12 AR084222]. W. Oliver Tobin has received research grant funding from the National Institutes of Health, the Mayo Clinic Center for MS and Autoimmune Neurology and book royalties from the publication of Mayo Clinic Cases in Neuroimmunology (Mayo Clinic Scientific Press) 2022.
